PubRank

Edison T Liu

Author PubWeight™ 298.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A global map of p53 transcription-factor binding sites in the human genome. Cell 2006 20.65
2 International network of cancer genome projects. Nature 2010 20.35
3 Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet 2006 17.19
4 An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005 13.54
5 Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003 13.00
6 An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009 12.16
7 Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005 8.73
8 Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006 8.08
9 Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods 2005 7.87
10 Mapping human genetic diversity in Asia. Science 2009 7.40
11 Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007 6.71
12 Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003 5.99
13 Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007 5.85
14 RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol 2006 4.93
15 Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res 2009 4.47
16 Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res 2008 3.76
17 Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002 3.40
18 Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells 2005 3.16
19 Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 2004 2.77
20 Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006 2.69
21 A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010 2.62
22 Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 2005 2.51
23 Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res 2004 2.47
24 DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008 2.46
25 Regulation of estrogen receptor-mediated long range transcription via evolutionarily conserved distal response elements. J Biol Chem 2008 2.34
26 Transcriptome analysis of zebrafish embryogenesis using microarrays. PLoS Genet 2005 2.32
27 Identification of cell cycle-regulated genes in fission yeast. Mol Biol Cell 2004 2.29
28 Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002 2.21
29 Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A 2002 2.15
30 Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription- independent poising of chromatin. Immunity 2010 2.08
31 Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 2005 2.07
32 Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002 2.04
33 Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol 2010 2.04
34 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006 2.02
35 p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 2004 1.70
36 Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 2002 1.67
37 Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res 2011 1.67
38 JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res 2012 1.67
39 5' Long serial analysis of gene expression (LongSAGE) and 3' LongSAGE for transcriptome characterization and genome annotation. Proc Natl Acad Sci U S A 2004 1.64
40 GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011 1.58
41 Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 2008 1.57
42 Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 2004 1.57
43 The Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet 2010 1.56
44 Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res 2008 1.55
45 Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol 2011 1.55
46 Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005 1.51
47 Systematic deletion analysis of fission yeast protein kinases. Eukaryot Cell 2005 1.51
48 Dragon ERE Finder version 2: A tool for accurate detection and analysis of estrogen response elements in vertebrate genomes. Nucleic Acids Res 2003 1.49
49 Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005 1.48
50 Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell 2013 1.40
51 De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One 2009 1.39
52 Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 2002 1.38
53 Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 2005 1.38
54 Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005 1.36
55 The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res 2002 1.35
56 Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002 1.34
57 Optimal gene expression analysis by microarrays. Cancer Cell 2002 1.34
58 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res 2002 1.32
59 Genetic background is an important determinant of metastatic potential. Nat Genet 2003 1.31
60 Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res 2011 1.30
61 Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. PLoS Med 2006 1.23
62 Mutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003. BMC Infect Dis 2004 1.21
63 Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLoS Genet 2010 1.19
64 Multiplatform genome-wide identification and modeling of functional human estrogen receptor binding sites. Genome Biol 2006 1.17
65 HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003 1.15
66 A gene harvest revealing the archeology and complexity of human disease. Nat Genet 2007 1.15
67 Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 2007 1.11
68 Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 2006 1.11
69 SARS transmission pattern in Singapore reassessed by viral sequence variation analysis. PLoS Med 2005 1.11
70 Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res 2007 1.09
71 Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med 2006 1.08
72 Identification of Src transformation fingerprint in human colon cancer. Oncogene 2002 1.07
73 Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 2005 1.06
74 Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004 1.05
75 Detection of severe acute respiratory syndrome coronavirus in blood of infected patients. J Clin Microbiol 2004 1.04
76 Structural mutations in cancer: mechanistic and functional insights. Trends Genet 2012 1.03
77 Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol 2013 1.03
78 Global profiling of DNA replication timing and efficiency reveals that efficient replication/firing occurs late during S-phase in S. pombe. PLoS One 2007 1.03
79 Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 2004 1.02
80 Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. J Mol Endocrinol 2004 1.01
81 A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers. Genome Res 2002 1.01
82 Zebrafish whole-adult-organism chemogenomics for large-scale predictive and discovery chemical biology. PLoS Genet 2008 1.00
83 ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 2008 1.00
84 Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 2002 0.98
85 Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003 0.97
86 Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med 2011 0.95
87 Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia 2010 0.94
88 Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics 2012 0.94
89 Transcriptome kinetics of arsenic-induced adaptive response in zebrafish liver. Physiol Genomics 2006 0.94
90 cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. Carcinogenesis 2002 0.93
91 Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res 2006 0.93
92 A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis 2004 0.93
93 Primate-specific endogenous cis-antisense transcription in the human 5q31 protocadherin gene cluster. J Mol Evol 2005 0.93
94 Interrogating the transcriptome. Trends Biotechnol 2004 0.92
95 Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. Genome Biol 2004 0.90
96 BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res 2004 0.89
97 Long span DNA paired-end-tag (DNA-PET) sequencing strategy for the interrogation of genomic structural mutations and fusion-point-guided reconstruction of amplicons. PLoS One 2012 0.89
98 BEARR: Batch Extraction and Analysis of cis-Regulatory Regions. Nucleic Acids Res 2004 0.88
99 Liver X receptors regulate adrenal steroidogenesis and hypothalamic-pituitary-adrenal feedback. Mol Endocrinol 2006 0.87
100 Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. Hum Mol Genet 2006 0.87
101 HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer. Comb Chem High Throughput Screen 2003 0.86
102 Highly sensitive and reversible silicon nanowire biosensor to study nuclear hormone receptor protein and response element DNA interactions. Biosens Bioelectron 2010 0.85
103 The Cinderella effect: searching for the best fit between mouse models and human diseases. J Invest Dermatol 2013 0.85
104 Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase. Int J Cancer 2003 0.85
105 Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Genet Cytogenet 2003 0.84
106 Molecular conservation of estrogen-response associated with cell cycle regulation, hormonal carcinogenesis and cancer in zebrafish and human cancer cell lines. BMC Med Genomics 2011 0.84
107 Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. Mol Cancer Res 2008 0.84
108 Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. J Biol Chem 2005 0.83
109 Transcriptome profiling of estrogen-regulated genes in human primary osteoblasts reveals an osteoblast-specific regulation of the insulin-like growth factor binding protein 4 gene. Mol Endocrinol 2007 0.82
110 Pyrosequencing enhancement for better detection limit and sequencing homopolymers. Biochem Biophys Res Commun 2010 0.82
111 PPARG binding landscapes in macrophages suggest a genome-wide contribution of PU.1 to divergent PPARG binding in human and mouse. PLoS One 2012 0.81
112 Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. Mol Cell Biol 2002 0.81
113 Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Res 2011 0.81
114 BRCA1-mediated repression of select X chromosome genes. J Transl Med 2004 0.81
115 Self-assembled monolayer-assisted silicon nanowire biosensor for detection of protein-DNA interactions in nuclear extracts from breast cancer cell. Biosens Bioelectron 2010 0.80
116 Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients. Bioinformatics 2006 0.80
117 Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol 2008 0.79
118 Gold-nanoparticle-based assay for instantaneous detection of nuclear hormone receptor-response elements interactions. Anal Chem 2010 0.79
119 Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development. Hugo J 2010 0.78
120 Identification of Myc-mediated death response pathways by microarray analysis. J Biol Chem 2002 0.78
121 Integrative biology and systems biology. Mol Syst Biol 2005 0.78
122 Cancer genomes. Clin Chem 2010 0.77
123 A bioinformatics tool to select sequences for microarray studies of mouse models of oncogenesis. Bioinformatics 2002 0.77
124 Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem Biophys Res Commun 2004 0.77
125 Molecular oncodiagnostics: where we are and where we need to go. J Clin Oncol 2003 0.76
126 Functional chromatin features are associated with structural mutations in cancer. BMC Genomics 2014 0.76
127 The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity. Biochem J 2004 0.76
128 Grappling with cancer. Science 2013 0.75
129 Expression profiling and breast cancer biology. Breast Dis 2004 0.75
130 Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol 2017 0.75
131 Strategy for the design of custom cDNA microarrays. Biotechniques 2003 0.75
132 The emergence of 'The HUGO Journal'. Hugo J 2010 0.75
133 HGV2009 meeting: bigger and better studies provide more answers and more questions. Hum Mutat 2010 0.75